Treatment of older patients with advanced non-small cell lung cancer: A challenge.
Adenocarcinoma
/ drug therapy
Aged
Anaplastic Lymphoma Kinase
/ genetics
Antineoplastic Agents
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Clinical Decision-Making
ErbB Receptors
/ genetics
Geriatric Assessment
Humans
Lung Neoplasms
/ drug therapy
Molecular Targeted Therapy
Mutation
Patient Selection
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins B-raf
/ genetics
Translocation, Genetic
Chemotherapy
Geriatric assessment
Immunotherapy
Older patients with lung cancer
Targeted therapy
Treatment
Journal
Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
28
03
2018
revised:
27
06
2018
accepted:
19
09
2018
pubmed:
12
10
2018
medline:
28
7
2020
entrez:
11
10
2018
Statut:
ppublish
Résumé
With a median age of 70 years at diagnosis, lung cancer is a disease of older persons. As a consequence oncologists are confronted with an increasing older lung cancer population for which treatment decisions are needed. In the past years, the therapeutic landscape of advanced non-small cell lung cancer (NSCLC) has changed impressively with the introduction of targeted therapies and immunotherapy next to chemotherapy. Treatment choices for advanced NSCLC are mainly guided by different tumor-related characteristics. However, in older patients treatment decisions are more complex because of the scarcity of data from large randomized studies in older patients and the heterogeneity of this population with regards to different geriatric domains such as functional status, comorbidity and polypharmacy. The present manuscript reviews available data for the different treatment options for older patients with NSCLC as well as the use of geriatric assessment as an evaluation and guidance tool.
Identifiants
pubmed: 30301660
pii: S1879-4068(18)30110-3
doi: 10.1016/j.jgo.2018.09.008
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Antineoplastic Agents, Immunological
0
Protein Kinase Inhibitors
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
528-533Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.